Sensus Healthcare (SRTS) Aktienübersicht
Sensus Healthcare, Inc. ist ein Medizintechnikunternehmen, das Geräte für die Strahlentherapie herstellt und an Gesundheitsdienstleister weltweit verkauft. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 2/6 |
| Künftiges Wachstum | 2/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 6/6 |
| Dividenden | 0/6 |
SRTS Community Fair Values
Create NarrativeSee what 64 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$13.42
FV
79.2% unterbewertet intrinsischer Abschlag20.39%
Revenue growth p.a.
1.6k
users have viewed this narrative6users have liked this narrative
0users have commented on this narrative
44users have followed this narrative
Sensus Healthcare, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$2.79 |
| 52-Wochen-Hoch | US$5.92 |
| 52-Wochen-Tief | US$2.66 |
| Beta | 1.09 |
| 1 Monat Veränderung | -12.54% |
| 3 Monate Veränderung | -32.12% |
| 1 Jahr Veränderung | -41.01% |
| 3 Jahre Veränderung | 0.36% |
| 5 Jahre Veränderung | -36.59% |
| Veränderung seit IPO | -52.31% |
Aktuelle Nachrichten und Updates
Narrativ-Update • Jun 04
SRTS: 2026 Reimbursement Codes Will Support Long Term Earnings Potential
Analysts have reduced their price target on Sensus Healthcare by $1 to $6, reflecting a lower fair value estimate and sharply reduced profit margin assumptions, partly offset by expectations for continued revenue growth from the SRT platform, supported by new reimbursement codes planned for 2026. Analyst Commentary Recent research points to a more cautious tone around Sensus Healthcare, with the trimmed price target reflecting reduced profit margin assumptions, even as analysts still factor in potential revenue contribution from the SRT platform and future reimbursement changes planned for 2026.
Narrativ-Update • May 19
SRTS: Future Returns Will Hinge On 2026 Reimbursement Code Reset
Analysts have trimmed their price target on Sensus Healthcare from $6.88 to $5.75, citing revised fair value assumptions that factor in updated expectations for revenue growth, profit margins and a much higher future P/E multiple linked to anticipated demand for the SRT platform and new 2026 reimbursement codes. Analyst Commentary Recent research highlights both optimism and caution around Sensus Healthcare as analysts recalibrate their expectations and fair value work.Recent updates
Narrativ-Update • Jun 04
SRTS: 2026 Reimbursement Codes Will Support Long Term Earnings Potential
Analysts have reduced their price target on Sensus Healthcare by $1 to $6, reflecting a lower fair value estimate and sharply reduced profit margin assumptions, partly offset by expectations for continued revenue growth from the SRT platform, supported by new reimbursement codes planned for 2026. Analyst Commentary Recent research points to a more cautious tone around Sensus Healthcare, with the trimmed price target reflecting reduced profit margin assumptions, even as analysts still factor in potential revenue contribution from the SRT platform and future reimbursement changes planned for 2026.Narrativ-Update • May 19
SRTS: Future Returns Will Hinge On 2026 Reimbursement Code Reset
Analysts have trimmed their price target on Sensus Healthcare from $6.88 to $5.75, citing revised fair value assumptions that factor in updated expectations for revenue growth, profit margins and a much higher future P/E multiple linked to anticipated demand for the SRT platform and new 2026 reimbursement codes. Analyst Commentary Recent research highlights both optimism and caution around Sensus Healthcare as analysts recalibrate their expectations and fair value work.
Narrativ-Update • Apr 25
SRTS: 2026 Reimbursement Codes And New Platform Rollout Will Drive Upside
Narrative Update Overview Analysts have trimmed their average price target on Sensus Healthcare from $8.00 to $7.50, reflecting mixed views that balance expectations for stronger SRT platform revenue supported by new 2026 reimbursement codes, alongside the impact of recent quarterly results that fell short due to no sales from a key customer. Analyst Commentary Bullish analysts remain constructive on Sensus Healthcare, pointing to the company’s SRT platform and upcoming reimbursement changes as key elements that could support long term growth.Narrativ-Update • Apr 10
SRTS: 2026 Reimbursement Shift Will Support Future Skin Therapy Adoption
Analysts have updated the price target range for Sensus Healthcare. One analyst raised the target to $7.50, citing expectations for SRT platform revenue supported by new 2026 reimbursement codes.Narrativ-Update • Mar 27
SRTS: Reimbursement Shift In 2026 Will Drive Future Upside Potential
Narrative Update: Sensus Healthcare (SRTS) The blended analyst price target for Sensus Healthcare has shifted from $8 to $7.50. Analysts are balancing expectations for very strong SRT platform revenue in 2026, tied to new reimbursement codes, with the impact of Q4 results that missed forecasts due to no sales from the company’s largest customer.Narrativ-Update • Mar 10
SRTS: Future Upside Will Depend On 2026 Reimbursement Code Changes
Analysts have nudged their fair value estimate for Sensus Healthcare slightly higher to $6.88, reflecting mixed recent research in which one firm trimmed its price target to $6 after weak Q4 results, while another initiated coverage with a more upbeat $7.50 target tied to expectations for the SRT platform and 2026 reimbursement changes. Analyst Commentary Bullish Takeaways Bullish analysts point to the SRT-100/Vision platform as the core driver of the current fair value view, given its focus on treating both oncological and non-oncological skin conditions, which supports their more constructive stance on long term growth potential.Narrativ-Update • Feb 24
SRTS: Future Upside Will Hinge On Reducing Largest Customer Concentration Risk
Narrative Update on Sensus Healthcare Analysts have trimmed their price target on Sensus Healthcare to $6 from $8, pointing to Q4 results that came in well below their expectations after the company reported no sales from its largest customer. Analyst Commentary Analysts are adjusting their views on Sensus Healthcare after the latest Q4 report, with the lower price target reflecting both execution concerns and how the market may now be valuing the shares.Analyseartikel • Feb 15
Sensus Healthcare, Inc. (NASDAQ:SRTS) Just Reported And Analysts Have Been Cutting Their Estimates
As you might know, Sensus Healthcare, Inc. ( NASDAQ:SRTS ) last week released its latest annual, and things did not...Narrativ-Update • Feb 10
SRTS: Auditor Transition And Margin Outlook Will Support Future Upside
Analysts have reduced their price target on Sensus Healthcare to US$20.65 from US$21.29, reflecting updated assumptions that include slightly higher projected revenue growth, a modestly stronger profit margin profile, and a marginally lower future P/E multiple. What's in the News Auditor change: Sensus Healthcare's Audit Committee dismissed Berkowitz Pollack Brant Advisors + CPAs, LLP and approved Carr, Riggs & Ingram, LLC as the new independent registered public accounting firm following CRI's acquisition of certain BPB capital markets assets, effective January 1, 2026 (Key Developments).Narrativ-Update • Jan 25
SRTS: Slightly Improved Outlook And Auditor Transition Will Support Future Upside
Analysts have raised their price target on Sensus Healthcare by a small amount, citing slightly higher assumptions for revenue growth and profit margins, along with a modestly lower discount rate and a marginally reduced future P/E multiple. What's in the News The Audit Committee of Sensus Healthcare's Board of Directors dismissed Berkowitz Pollack Brant Advisors + CPAs, LLP as the independent registered public accounting firm and approved Carr, Riggs & Ingram, LLC as the new auditor, following CRI's acquisition of certain capital markets assets from BPB effective January 1, 2026 (company filing).Analyseartikel • Jan 14
Sensus Healthcare, Inc.'s (NASDAQ:SRTS) Share Price Boosted 38% But Its Business Prospects Need A Lift Too
Despite an already strong run, Sensus Healthcare, Inc. ( NASDAQ:SRTS ) shares have been powering on, with a gain of 38...Narrativ-Update • Jan 10
SRTS: Keloid Treatment Breakthrough Will Support Stronger Prospects Despite Trimmed Outlook
Narrative Update on Sensus Healthcare Analysts have modestly raised their price target on Sensus Healthcare, citing slightly adjusted assumptions for discount rate, revenue growth, profit margin and future P/E. Together, these adjustments support a higher fair value estimate now framed at US$8.00.Narrativ-Update • Dec 26
SRTS: Keloid Treatment Breakthrough Will Drive Stronger Prospects Despite Trimmed Outlook
Analysts have modestly lifted their price target on Sensus Healthcare to reflect slightly faster expected revenue growth and improving profit margins, even as they temper future valuation multiples. Valuation Changes Discount Rate has risen slightly from 7.69% to 7.70%, reflecting a marginally higher required return.Narrativ-Update • Dec 12
SRTS: Keloid Treatment Breakthrough Will Drive Stronger Prospects Despite Trimmed Outlook
Analysts have trimmed their price target on Sensus Healthcare to approximately 8 dollars from about 10 dollars, citing softer expected revenue growth, lower projected profit margins, and a higher assumed future price to earnings multiple that together point to a more conservative valuation outlook. What's in the News Peer reviewed data from a single center retrospective study in Dermatologic Therapy show that Sensus Healthcare's superficial radiotherapy technology combined with punch excision significantly improved keloid outcomes over one year, including reductions in pain, itching, thickness and irregularity of scars, with no severe adverse reactions reported (study in Dermatologic Therapy).Analyseartikel • Nov 19
Sensus Healthcare, Inc. (NASDAQ:SRTS) Stock Rockets 26% But Many Are Still Ignoring The Company
The Sensus Healthcare, Inc. ( NASDAQ:SRTS ) share price has done very well over the last month, posting an excellent...Analyseartikel • Oct 04
Insufficient Growth At Sensus Healthcare, Inc. (NASDAQ:SRTS) Hampers Share Price
You may think that with a price-to-sales (or "P/S") ratio of 1.5x Sensus Healthcare, Inc. ( NASDAQ:SRTS ) is a stock...Narrativ-Update • Sep 04
Increased CMS Reimbursement And International Expansion Will Unlock Demand
With no new analyst reasoning provided and both the discount rate and future P/E ratio remaining stable, the consensus fair value for Sensus Healthcare is unchanged at $8.00. What's in the News Sensus Healthcare's entire superficial radiation therapy (SRT) system portfolio received Medical Device Single Audit Program (MDSAP) certification.Analyseartikel • Jul 12
Returns On Capital Are Showing Encouraging Signs At Sensus Healthcare (NASDAQ:SRTS)
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Typically...Analyseartikel • May 06
Why Sensus Healthcare, Inc. (NASDAQ:SRTS) Could Be Worth Watching
While Sensus Healthcare, Inc. ( NASDAQ:SRTS ) might not have the largest market cap around , it received a lot of...Analyseartikel • Mar 13
Investors Shouldn't Be Too Comfortable With Sensus Healthcare's (NASDAQ:SRTS) Earnings
Despite posting some strong earnings, the market for Sensus Healthcare, Inc.'s ( NASDAQ:SRTS ) stock hasn't moved much...Analyseartikel • Feb 25
Sensus Healthcare, Inc. (NASDAQ:SRTS) Stock's 27% Dive Might Signal An Opportunity But It Requires Some Scrutiny
To the annoyance of some shareholders, Sensus Healthcare, Inc. ( NASDAQ:SRTS ) shares are down a considerable 27% in...Analyseartikel • Feb 08
Revenue Beat: Sensus Healthcare, Inc. Beat Analyst Estimates By 5.6%
Shareholders in Sensus Healthcare, Inc. ( NASDAQ:SRTS ) had a terrible week, as shares crashed 29% to US$5.84 in the...Neues Narrativ • Jan 07
SRTS Market Outlook
Sensus Healthcare (NASDAQ: SRTS) operates in the Healthcare sector and is part of the Medical Devices industry. Specifically, it focuses on the development and commercialization of non-invasive SuperfAnalyseartikel • Dec 18
We Think Sensus Healthcare (NASDAQ:SRTS) Might Have The DNA Of A Multi-Bagger
There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...Analyseartikel • Nov 19
Results: Sensus Healthcare, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Shareholders of Sensus Healthcare, Inc. ( NASDAQ:SRTS ) will be pleased this week, given that the stock price is up 19...Analyseartikel • Nov 12
Sensus Healthcare, Inc. (NASDAQ:SRTS) Doing What It Can To Lift Shares
It's not a stretch to say that Sensus Healthcare, Inc.'s ( NASDAQ:SRTS ) price-to-earnings (or "P/E") ratio of 17.4x...Analyseartikel • Oct 03
At US$6.10, Is It Time To Put Sensus Healthcare, Inc. (NASDAQ:SRTS) On Your Watch List?
While Sensus Healthcare, Inc. ( NASDAQ:SRTS ) might not have the largest market cap around , it saw a significant share...
Neues Narrativ • Sep 28
Fair Deal Agreement And Global Expansion Set To Revolutionize Revenue And Margins
Strategic shift towards recurring revenue with the Fair Deal Agreement model indicates potential for significant revenue growth from 2025.Analyseartikel • May 12
Returns At Sensus Healthcare (NASDAQ:SRTS) Are On The Way Up
To find a multi-bagger stock, what are the underlying trends we should look for in a business? One common approach is...Analyseartikel • Apr 16
Potential Upside For Sensus Healthcare, Inc. (NASDAQ:SRTS) Not Without Risk
With a price-to-sales (or "P/S") ratio of 2.1x Sensus Healthcare, Inc. ( NASDAQ:SRTS ) may be sending bullish signals...Analyseartikel • Feb 11
Sensus Healthcare, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
The investors in Sensus Healthcare, Inc. 's ( NASDAQ:SRTS ) will be rubbing their hands together with glee today, after...Aktionärsrenditen
| SRTS | US Medical Equipment | US Markt | |
|---|---|---|---|
| 7D | 3.0% | -1.0% | 1.4% |
| 1Y | -41.0% | -20.7% | 25.7% |
Rendite im Vergleich zur Industrie: SRTS unter dem Niveau der Branche US Medical Equipment , die im vergangenen Jahr eine Rendite von -20.7% erzielte.
Rendite vs. Markt: SRTS hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 25.7 erzielte.
Preisvolatilität
| SRTS volatility | |
|---|---|
| SRTS Average Weekly Movement | 10.2% |
| Medical Equipment Industry Average Movement | 8.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiler Aktienkurs: SRTS hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: SRTSDie wöchentliche Volatilität (10%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2010 | 60 | Joe Sardano | sensushealthcare.com |
Sensus Healthcare, Inc. ist ein Medizintechnikunternehmen, das Geräte für die Strahlentherapie herstellt und an Gesundheitsdienstleister weltweit verkauft. Das Unternehmen nutzt die oberflächliche Strahlentherapie, eine Röntgentechnologie mit niedriger Energie, in seinem Portfolio von Behandlungsgeräten. Es bietet SRT-100, ein oberflächliches Röntgensystem mit niedriger Energie, das Patienten eine Alternative zur Operation bei der Behandlung von Nicht-Melanom-Hautkrebs, einschließlich Basalzell- und Plattenepithelkarzinomen, sowie anderen Hautkrankheiten wie Keloiden bietet; und SRT-100 Vision, das dem Benutzer eine auf die oberflächliche Strahlentherapie zugeschnittene Behandlungsplanungsanwendung bietet, die ein eingebettetes Hochfrequenz-Ultraschall-Bildgebungsmodul, eine volumetrische Tumoranalyse, die Planung von Strahlenrändern und Dosimetrieparameter integriert.
Sensus Healthcare, Inc.'s Grundlagenzusammenfassung
| SRTS grundlegende Statistiken | |
|---|---|
| Marktanteil | US$45.93m |
| Gewinn(TTM) | -US$7.77m |
| Umsatz(TTM) | US$22.53m |
2.0x
Kurs-Umsatz-Verhältnis-5.9x
Kurs-Gewinn-Verhältnis Ist SRTS zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| SRTS Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$22.53m |
| Kosten der Einnahmen | US$14.03m |
| Bruttogewinn | US$8.50m |
| Sonstige Ausgaben | US$16.28m |
| Gewinn | -US$7.77m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -0.47 |
| Bruttomarge | 37.74% |
| Nettogewinnspanne | -34.50% |
| Schulden/Eigenkapital-Verhältnis | 0% |
Wie hat sich SRTS auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/06/21 14:21 |
| Aktienkurs zum Tagesende | 2026/06/18 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Sensus Healthcare, Inc. wird von 8 Analysten beobachtet. 4 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Scott Henry | Alliance Global Partners |
| Andrew D'Silva | B. Riley Securities, Inc. |
| Alexander Nowak | Craig-Hallum Capital Group LLC |